At the time of writing, NovoCure Ltd [NVCR] stock is trading at $12.66, up 0.48%. An important factor to consider is whether the stock is rising or falling in short-term value. The NVCR shares have gain 3.86% over the last week, with a monthly amount glided 13.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on July 25, 2025, when Wells Fargo downgraded its rating to a Equal Weight but kept the price target unchanged to $14.50 for it. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on July 08, 2025, and set its price target to $30. On December 02, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $30 on the stock. H.C. Wainwright upgraded its rating to a Buy and increased its price target to $30 on October 16, 2024. H.C. Wainwright downgraded its rating to Neutral for this stock on August 28, 2023, and downed its price target to $25. In a note dated August 08, 2023, Piper Sandler upgraded an Overweight rating on this stock but restated the target price of $45.
For the past year, the stock price of NovoCure Ltd fluctuated between $10.87 and $34.13. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $12.66 at the most recent close of the market. An investor can expect a potential return of 14.53% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
According to NovoCure Ltd [NASDAQ:NVCR], the company’s sales were 630.16M for trailing twelve months, which represents an 5.62% jump. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.23%, and Net Profit Margin reading is -0.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.48 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.43 points at the first support level, and at 12.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.87, and for the 2nd resistance point, it is at 13.07.
Ratios To Look Out For
It is important to note that NovoCure Ltd [NASDAQ:NVCR] has a current ratio of 1.45. On the other hand, the Quick Ratio is 1.39, and the Cash Ratio is 0.2. Considering the valuation of this stock, the price to sales ratio is 2.25, the price to book ratio is 4.05.
Transactions by insiders
Recent insider trading involved Cordova Ashley, Chief Executive Officer, that happened on Sep 05 ’25 when 81550.0 shares were purchased. Chief Financial Officer, Brackmann Christoph completed a deal on Jul 29 ’25 to buy 20000.0 shares. Meanwhile, Director Stafford Kristin sold 999.0 shares on Jun 03 ’25.
